Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
86.67
-0.15 (-0.17%)
At close: May 27, 2026, 4:00 PM EDT
86.67
0.00 (0.00%)
After-hours: May 27, 2026, 4:57 PM EDT
Dianthus Therapeutics Employees
Dianthus Therapeutics had 92 employees as of December 31, 2025. The number of employees increased by 14 or 17.95% compared to the previous year.
Employees
92
Change (1Y)
14
Growth (1Y)
17.95%
Revenue / Employee
$14,522
Profits / Employee
-$1,887,609
Market Cap
4.74B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 92 | 14 | 17.95% |
| Dec 31, 2024 | 78 | 25 | 47.17% |
| Dec 31, 2023 | 53 | 21 | 65.63% |
| Jun 30, 2023 | 43 | - | - |
| Mar 31, 2023 | 32 | - | - |
| Dec 31, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Caris Life Sciences | 1,846 |
| Travere Therapeutics | 497 |
| TG Therapeutics | 399 |
| CRISPR Therapeutics AG | 393 |
| Xenon Pharmaceuticals | 370 |
| Cogent Biosciences | 258 |
| NewAmsterdam Pharma Company | 100 |
DNTH News
- 1 day ago - Dianthus Therapeutics to Participate in Two Investor Conferences - GlobeNewsWire
- 8 days ago - Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases - GlobeNewsWire
- 16 days ago - Dianthus price target lowered to $120 from $122 at Evercore ISI - TheFly
- 20 days ago - Dianthus price target raised to $125 from $123 at Raymond James - TheFly
- 21 days ago - LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis - GlobeNewsWire
- 22 days ago - Dianthus reports Q1 EPS (85c), consensus ($1.10) - TheFly
- 22 days ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results - GlobeNewsWire
- 22 days ago - Dianthus Therapeutics Earnings release: Q1 2026 - Filings